RESI Innovation Challenge

If you are a scientist-entrepreneur or fundraising CEO starting to accumulate compelling proof-of-concept animal data or early stage clinical data, the RESI Innovation Challenge is for you. The 30 most innovative applicants will be hand selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference. Presenters will gain additional exposure to investors and potential partners by showcasing their companies and products in a poster format. Unlike traditional 5- to 15-minute pitch presentations that do not allow any real interaction and provide no actionable feedback from investors, the RESI Innovation Challenge enables executives to pitch directly to attendees, generating more in-depth conversations with more investors, more frequently throughout the event.

RESI JPM 2018 Innovation Challenge Winners

First Prize:

With a $6 million lead investment from the UK-based Wellcome Trust ($26 billion in assets), CorInnova is developing an innovative minimally invasive cardiac assist device to treat heart failure. The collapsible soft robotic direct cardiac compression device, deployed minimally invasively into the pericardial space around the heart, does not touch the blood. The device should reduce hospital length of stay from 30 to 4 days and adverse events vs. LVADS by 40%. It will expand the eligible patient population 3 to 4X to an addressable market of up to $14 billion. CorInnova has a world-class team. First-in-human trials are anticipated to begin in 18 months. Three similar cardiac companies with only 10 patients’ data sold for $250 to $400 million in cash.

Second Prize:

ImmunoBiochem is a privately held biopharmaceutical company solving the problem of tumor heterogeneity by targeting unique proteins enriched in the secretomes of cancer cells with Antibody Drug Conjugates (ADCs) – a promising class of biological anticancer therapeutics. ImmunoBiochem has identified a class of molecular targets that are secreted by cancer cells, but not healthy cells, and possess unique properties enabling the highly-selective delivery of toxic payloads to cancer cells, while leaving normal cells unharmed. ImmunoBiochem’s next-generation biologics aim to offer a superior safety profile and broad therapeutic window. Lead candidate, IMB-212, is aimed at a well-characterized cancer biomarker supported by a wealth of clinical data, and is being developed for Triple-Negative Breast Cancer (TNBC) – an aggressive disease for which no targeted biologics treatment options are available.

Third Prize:

Biorez is an early-stage regenerative medicine company developing a bioresorbable scaffold for ACL reconstruction. Despite over 400,000 procedures each year, current surgical options are limited to autograft tissue, which requires a patient to sacrifice their own tendon, or allograft tissue, which is harvested from cadavers and has a higher failure rate. There is a large, unmet clinical need for a consistent, off-the-shelf device for ligament regeneration. The Biorez device provides the necessary strength to support physical activity, while its highly porous, proprietary structure facilitates a patient’s own cells to follow the scaffold and regenerate new functional tissue. The company is supported by early-stage VC investors, world-class scientific advisors, and a dedicated team to commercialize this exciting technology.

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital invested will be tallied up and the top three winners will receive prizes and be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

RESI JPM 2018 Innovation Challenge Companies



MedTech Device

Healthcare IT